Does the media favor MDXG or TNYA?

In the previous week, Tenaya Therapeutics had 16 more articles in the media than MiMedx Group. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 1 mentions for MiMedx Group. Tenaya Therapeutics' average media sentiment score of 0.46 beat MiMedx Group's score of 0.46 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AVTE or TNYA?

Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 442.45%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has better valuation & earnings, AVTE or TNYA?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A

Is AVTE or TNYA more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Tenaya Therapeutics N/A -83.75% -66.53%

Which has better earnings & valuation, TNYA or NVCT?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is TNYA or NVCT more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Nuvectis Pharma N/A -184.25% -105.24%

Does the media prefer TNYA or NVCT?

In the previous week, Nuvectis Pharma had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 18 mentions for Nuvectis Pharma and 17 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.46 beat Nuvectis Pharma's score of 0.30 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, TNYA or MPLT?

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is TNYA or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Maplight Therapeutics N/A N/A N/A

Does the media favor TNYA or MPLT?

In the previous week, Tenaya Therapeutics had 12 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Tenaya Therapeutics' score of 0.46 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TNYA or ALT?

In the previous week, Tenaya Therapeutics had 12 more articles in the media than Altimmune. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 5 mentions for Altimmune. Tenaya Therapeutics' average media sentiment score of 0.46 beat Altimmune's score of 0.15 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tenaya Therapeutics (TNYA) Competitors

$0.74 +0.01 (+1.46%)

As of 04:00 PM Eastern

Compare

TNYA vs. MDXG, AVTE, NVCT, MPLT, and ALT

Should you buy Tenaya Therapeutics stock or one of its competitors? Tenaya Therapeutics's main competitors and comparable companies include MiMedx Group (MDXG), Aerovate Therapeutics (AVTE), Nuvectis Pharma (NVCT), Maplight Therapeutics (MPLT), and Altimmune (ALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tenaya Therapeutics compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

MiMedx Group currently has a consensus price target of $8.50, indicating a potential upside of 99.06%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 442.45%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Tenaya Therapeutics had 16 more articles in the media than MiMedx Group. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 1 mentions for MiMedx Group. Tenaya Therapeutics' average media sentiment score of 0.46 beat MiMedx Group's score of 0.46 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to Tenaya Therapeutics' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

MiMedx Group has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.49	$48.58M	$0.04	106.75
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

MiMedx Group has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, meaning that its stock price is 183% more volatile than the broader market.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

MiMedx Group and Tenaya Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Tenaya Therapeutics had 17 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 0 mentions for Aerovate Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.46 beat Aerovate Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Tenaya Therapeutics	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tenaya Therapeutics' return on equity of -83.75% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, meaning that its stock price is 183% more volatile than the broader market.

Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 442.45%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Tenaya Therapeutics beats Aerovate Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Nuvectis Pharma?

Tenaya Therapeutics (NASDAQ:TNYA) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Tenaya Therapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 442.45%. Nuvectis Pharma has a consensus price target of $35.00, suggesting a potential upside of 85.38%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

In the previous week, Nuvectis Pharma had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 18 mentions for Nuvectis Pharma and 17 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.46 beat Nuvectis Pharma's score of 0.30 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tenaya Therapeutics' return on equity of -83.75% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Nuvectis Pharma	N/A	-184.25%	-105.24%

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tenaya Therapeutics beats Nuvectis Pharma on 10 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Maplight Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Maplight Therapeutics' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Maplight Therapeutics	N/A	N/A	N/A

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 442.45%. Maplight Therapeutics has a consensus price target of $31.17, suggesting a potential upside of 155.88%. Given Tenaya Therapeutics' higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

In the previous week, Tenaya Therapeutics had 12 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Tenaya Therapeutics' score of 0.46 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Maplight Therapeutics beats Tenaya Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Altimmune?

Tenaya Therapeutics (NASDAQ:TNYA) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Tenaya Therapeutics had 12 more articles in the media than Altimmune. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 5 mentions for Altimmune. Tenaya Therapeutics' average media sentiment score of 0.46 beat Altimmune's score of 0.15 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 442.45%. Altimmune has a consensus price target of $15.71, suggesting a potential upside of 415.22%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tenaya Therapeutics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Altimmune has higher revenue and earnings than Tenaya Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Altimmune	$40K	14,828.34	-$88.09M	-$0.93	N/A

Tenaya Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Altimmune	-214,860.98%	-42.57%	-35.57%

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tenaya Therapeutics has a beta of 2.83, meaning that its share price is 183% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Tenaya Therapeutics beats Altimmune on 11 of the 16 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$157.71M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.39	5.30	210.34	20.96
Price / Sales	N/A	1,255.26	588.78	86.31
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	1.29	17.66	11.27	6.42
Net Income	-$90.60M	-$13.25M	$3.45B	$347.03M
7 Day Performance	1.15%	5.36%	3.56%	2.48%
1 Month Performance	-15.28%	-1.74%	-0.58%	-1.04%
1 Year Performance	10.24%	61.36%	77.52%	23.22%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	3.1984 of 5 stars	$0.74 +1.5%	$4.00 +442.4%	+8.7%	$157.71M	N/A	N/A	110	News Coverage Earnings Report Upcoming Earnings Analyst Revision
MDXG MiMedx Group	2.8 of 5 stars	$4.27 +3.4%	$8.50 +99.1%	-38.2%	$601.99M	$418.63M	106.78	870
AVTE Aerovate Therapeutics	N/A	$19.75 -1.3%	N/A	+193.2%	$572.45M	N/A	N/A	20	Gap Up High Trading Volume
NVCT Nuvectis Pharma	3.9242 of 5 stars	$21.60 +0.4%	$35.00 +62.0%	+215.8%	$570.83M	N/A	N/A	8	Earnings Report
MPLT Maplight Therapeutics	3.3979 of 5 stars	$12.55 -3.6%	$34.42 +174.2%	N/A	$554.89M	N/A	N/A	109	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. MDXG, AVTE, NVCT, MPLT, and ALT

How does Tenaya Therapeutics compare to MiMedx Group?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Summary

How does Tenaya Therapeutics compare to Nuvectis Pharma?

Summary

How does Tenaya Therapeutics compare to Maplight Therapeutics?

Summary

How does Tenaya Therapeutics compare to Altimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. MDXG, AVTE, NVCT, MPLT, and ALT

How does Tenaya Therapeutics compare to MiMedx Group?

Do analysts rate MDXG or TNYA?

Does the media favor MDXG or TNYA?

Is MDXG or TNYA more profitable?

Which has better valuation & earnings, MDXG or TNYA?

Which has more volatility and risk, MDXG or TNYA?

Do institutionals & insiders have more ownership in MDXG or TNYA?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Does the media favor AVTE or TNYA?

Which has better valuation & earnings, AVTE or TNYA?

Do institutionals & insiders have more ownership in AVTE or TNYA?

Is AVTE or TNYA more profitable?

Which has more volatility and risk, AVTE or TNYA?

Do analysts rate AVTE or TNYA?

Summary

How does Tenaya Therapeutics compare to Nuvectis Pharma?

Which has more risk and volatility, TNYA or NVCT?

Do analysts rate TNYA or NVCT?

Which has better earnings & valuation, TNYA or NVCT?

Does the media prefer TNYA or NVCT?

Is TNYA or NVCT more profitable?

Do institutionals and insiders hold more shares of TNYA or NVCT?

Summary

How does Tenaya Therapeutics compare to Maplight Therapeutics?

Is TNYA or MPLT more profitable?

Which has better earnings & valuation, TNYA or MPLT?

Do analysts rate TNYA or MPLT?

Does the media favor TNYA or MPLT?

Do institutionals and insiders hold more shares of TNYA or MPLT?

Summary

How does Tenaya Therapeutics compare to Altimmune?

Does the media refer more to TNYA or ALT?

Do analysts prefer TNYA or ALT?

Which has higher earnings & valuation, TNYA or ALT?

Is TNYA or ALT more profitable?

Do institutionals and insiders have more ownership in TNYA or ALT?

Which has more volatility and risk, TNYA or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools